Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website; (3) the federal government Internet portal; or (4) a web search conducted using a commercial search engine such as
Accession Number ADA583509
Title Production of a Novel OX40 Ligand for Clinical Use.
Publication Date Oct 2012
Media Count 98p
Personal Author A. D. Weinberg
Abstract Cancer cells have evolved to evade immune-mediated destruction through several documented mechanisms. Our group has developed a technique to enhance immune function in tumor-bearing hosts by targeting a protein on the surface of white blood cells, termed OX40. This type of immune modulation leads to therapeutic benefit in tumor-bearing mice. We have produced a protein that binds to the human OX40 protein and activates human white blood cells. We have a cell line that produces high quantities of this protein and our goal is to test this protein for safety and efficacy in non-human primates so that we can obtain FDA approval for clinical trials in cancer patients. The long-range goal of this proposal is translate these findings to prostate cancer patients.
Keywords Blood cells
Clinical medicine
Clinical trials

Source Agency Non Paid ADAS
NTIS Subject Category 57A - Anatomy
57S - Physiology
57E - Clinical Medicine
Corporate Author Angov (Evelina), Bethesda, MD.
Document Type Technical report
Title Note Annual rept. 30 Sep 2011-29 Sep 2012.
NTIS Issue Number 1401
Contract Number W81XWH-11-1-0345

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader